ניקסואה מודיעה על הצעת הנפקה של מניות רגילות
מונט-סן-גיבר, בלגיה – 4 ביוני 2026, GLOBE NEWSWIRE –
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות
רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), הודיעה היום על תחילתה של
הנפקה ציבורית מוצעת בארצות הברית, שעשויה לכלול מניות הנמכרות בהנפקה פרטית
למשקיעים מוסדיים או כשירים מסוימים מחוץ לארצות הברית, כולל בתוך האיחוד האירופי.
כל המניות הרגילות מוצעות על ידי Nyxoah ואין בעלי מניות מוכרים
המשתתפים בהנפקה המוצעת. בנוסף, Nyxoah צופה להעניק לחתמי ההנפקה
אופציה של 30 יום לרכישת מניות רגילות נוספות בסכום של עד 15% ממספר המניות
הנמכרות בהנפקה. ההנפקה המוצעת כפופה לתנאי שוק ותנאי אחרים, ואין כל ערובה לגבי
האם או מתי ההנפקה תושלם, או לגבי גודל ההנפקה או תנאיה בפועל.
Nyxoah Announces Proposed Offering of Ordinary Shares
Mont-Saint-Guibert, Belgium – June 4, 2026, GLOBE NEWSWIRE –
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical
technology company focused on developing innovative solutions for Obstructive
Sleep Apnea (OSA), today announced the commencement of a proposed underwritten
public offering in the United States, which may include shares sold in a
private offering to certain qualified or institutional investors outside the
United States, including within the European Union. All of the ordinary shares
are being offered by Nyxoah and there are no selling shareholders participating
in the proposed offering. In addition, Nyxoah expects to grant the underwriters
a 30-day option to purchase additional ordinary shares in an amount of up to
15% of the number of shares sold in the offering. The proposed offering is
subject to market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size or
terms of the offering.
Nyxoah intends to use the net proceeds from
the proposed offering (i) for expanding commercialization activities in the
United States; (ii) to further finance research and development activities
related to Genio system upgrades, re-designing its products for
manufacturability and cost reduction initiatives, and to continue to build a
pipeline of new technologies and explore potential collaboration opportunities
in the field of monitoring and diagnostics for OSA; (iii) to advance
commercialization of the Genio system in its initial target markets outside of
the United States and to continue gathering clinical data and to support
physician initiated clinical research projects related to OSA patient
treatments; and (iv) for other general corporate purposes, including, but not
limited to, working capital, repayment of debt financing, capital expenditures,
investments, acquisitions, should the Company choose to pursue any, and
collaborations.
BofA Securities is acting as the lead
bookrunner for the offering. Bank Degroof Petercam SA/NV is acting as an
additional bookrunner and B. Riley is acting as a co-manager for the offering.
The public offering in the United States will
be made pursuant to an effective shelf registration statement on Form F-3 (File
No. 333-285982) that was filed by Nyxoah with the U.S. Securities and Exchange
Commission (the “SEC”) and became effective on April 1, 2025. A preliminary
prospectus supplement will be filed with the SEC and the accompanying
prospectus relating to and describing the terms of the offering will be and are
available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus
supplement, when available, and the accompanying prospectus may be obtained by
contacting BofA Securities at 201 North Tryon Street, NC1-022-02-25, Charlotte,
NC 28255-0001, Attention: Prospectus Department, at dg.prospectus_requests@bofa.com or by telephone at 1-800-294-1322.
This press release shall not constitute an
offer to sell or a solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such state or
other jurisdiction.
About Nyxoah
Nyxoah is a medical technology company
focused on the development and commercialization of innovative solutions to
treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for OSA, the
world’s most common sleep disordered breathing condition that is associated
with increased mortality risk and cardiovascular comorbidities. Nyxoah is
driven by the vision that OSA patients should enjoy restful nights and feel
enabled to live their life to its fullest.
Following the successful completion of the
BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah
completed two successful IPOs: on Euronext Brussels in September 2020 and
NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study,
Nyxoah received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company announced
positive outcomes from the DREAM IDE pivotal study and received approval from
the FDA for a subset of adult patients with moderate to severe OSA with an AHI
of greater than or equal to 15 and less than or equal to 65.
Caution – CE marked since 2019. FDA approved
in August 2025 as prescription-only device.
תגובות
הוסף רשומת תגובה